BR112016021985A8 - formulação farmacêutica e composto - Google Patents

formulação farmacêutica e composto

Info

Publication number
BR112016021985A8
BR112016021985A8 BR112016021985A BR112016021985A BR112016021985A8 BR 112016021985 A8 BR112016021985 A8 BR 112016021985A8 BR 112016021985 A BR112016021985 A BR 112016021985A BR 112016021985 A BR112016021985 A BR 112016021985A BR 112016021985 A8 BR112016021985 A8 BR 112016021985A8
Authority
BR
Brazil
Prior art keywords
compounds
obese
compound
administered
pharmaceutical formulation
Prior art date
Application number
BR112016021985A
Other languages
English (en)
Other versions
BR112016021985A2 (pt
BR112016021985B1 (pt
Inventor
Mazitschek Ralph
Özcam Umut
Original Assignee
Childrens Medical Ct Corp
Massachusetts Gen Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Ct Corp, Massachusetts Gen Hospital filed Critical Childrens Medical Ct Corp
Publication of BR112016021985A2 publication Critical patent/BR112016021985A2/pt
Publication of BR112016021985A8 publication Critical patent/BR112016021985A8/pt
Publication of BR112016021985B1 publication Critical patent/BR112016021985B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30—Unsaturated compounds
    • C07C62/38—Unsaturated compounds containing keto groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids

Abstract

formulação farmacêutica, método para induzir perda de peso ou redução de gordura corporal, método para melhorar a homeostase da glicose e composto. compostos de triterpeno pentacíclico são providos na = presente invenção. também são providas formulações farmacêuticos contendo uma quantidade terapeuticamente eficaz de um ou mais dos compostos, ou sais farmaceuticamente aceitos ou pró-fármacos destes, e m combinação com um ou mais excipientes farmaceuticamente aceitos. as formulações farmacêuticas podem ser administradas a um paciente pré-obeso, obeso ou com obesidade mórbida a fim de induzir perda de peso, reduzir gordura corporal, reduzir ingestão de alimentos, melhorar a homeostase da glicose, prevenir a obesidade ou uma combinação disso. os compostos também podem ser coadministrados com leptina ou um análogo de leptina.
BR112016021985-6A 2014-03-26 2015-03-26 Formulação farmacêutica BR112016021985B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461970839P 2014-03-26 2014-03-26
US61/970,839 2014-03-26
PCT/US2015/022746 WO2015148802A1 (en) 2014-03-26 2015-03-26 Celastrol and derivatives for the treatment of obesity

Publications (3)

Publication Number Publication Date
BR112016021985A2 BR112016021985A2 (pt) 2017-08-15
BR112016021985A8 true BR112016021985A8 (pt) 2021-06-29
BR112016021985B1 BR112016021985B1 (pt) 2022-08-30

Family

ID=52823863

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016021985-6A BR112016021985B1 (pt) 2014-03-26 2015-03-26 Formulação farmacêutica

Country Status (10)

Country Link
US (3) US20150274634A1 (pt)
EP (1) EP3122347B1 (pt)
JP (1) JP2017513824A (pt)
CN (2) CN107073016A (pt)
AU (2) AU2015235979B2 (pt)
BR (1) BR112016021985B1 (pt)
CA (2) CA3044998A1 (pt)
ES (1) ES2813424T3 (pt)
RU (1) RU2706239C2 (pt)
WO (1) WO2015148802A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9115163B2 (en) 2007-10-19 2015-08-25 The Trustees Of Columbia University In The City Of New York DNA sequence with non-fluorescent nucleotide reversible terminators and cleavable label modified nucleotide terminators
US20170209408A1 (en) * 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
CA3002924A1 (en) 2015-10-23 2017-04-27 Erx Pharmaceuticals Inc. Analogs of celastrol
US10053693B2 (en) 2016-01-19 2018-08-21 Mubin I. Syed Method for controlling obesity using minimally invasive means
EP3471733A4 (en) * 2016-06-15 2020-02-05 Der Sarkissian, Shant REAGENTS, COMPOSITIONS AND METHODS FOR IMPROVING THE VIABILITY AND FUNCTIONALITY OF CELLS, TISSUES AND ORGANS
EP3480207A4 (en) 2016-07-04 2020-03-11 Xiamen University ORPHAN NUR77 NUCLEAR RECEPTOR LIGAND AND ITS APPLICATION
CN106243181A (zh) * 2016-07-29 2016-12-21 合肥中科玛卡生物技术有限公司 一种从苦瓜中提取雷公藤红素的方法
WO2018026810A1 (en) * 2016-08-03 2018-02-08 Vanderbilt University Treatment methods using celastrol
CN111821308B (zh) * 2019-04-15 2021-10-08 中国科学院上海药物研究所 雷藤舒在制备用于治疗非酒精性脂肪性肝病的药物中的应用
CN115023431B (zh) * 2019-09-12 2024-02-02 藤济(厦门)生物医药科技有限公司 三萜类化合物，其药物组合物和在治疗核受体亚家族4组成员1所介导疾病中的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650167A (en) * 1995-11-16 1997-07-22 Dawa Incorporated Method and composition for treating hepatitis B
EP1558271A4 (en) * 2002-10-21 2006-01-11 Metaproteomics Llc COMPOSITIONS TREATING OR INHIBITING PATHOLOGICAL CONDITIONS ASSOCIATED WITH INFLAMMATORY REACTION
US8236769B2 (en) * 2005-09-30 2012-08-07 Morinaga Milk Industry Co., Ltd. Agent for improving insulin resistance
CN101686951A (zh) * 2006-11-13 2010-03-31 纽约市哥伦比亚大学托管会 治疗糖尿病的选择性蛋白酶体抑制物
US8641155B2 (en) * 2007-07-26 2014-02-04 David Lee Modular furniture system
US7776894B2 (en) * 2007-08-17 2010-08-17 Burnham Institute For Medical Research Compositions and methods for inhibiting growth and metastasis of melanoma
CN101434635B (zh) * 2007-11-16 2012-05-16 上海华拓医药科技发展股份有限公司 一类具抗肿瘤活性的水溶性酚性三萜化合物及其制备方法
EP2271213A4 (en) * 2008-02-01 2011-06-29 Scripps Research Inst METHOD FOR THE TREATMENT OF A GRADE SUFFERED BY PROTEIN HOMEOSTASIS
US9132108B2 (en) * 2009-04-17 2015-09-15 Hiroshima University Pharmaceutical composition for ameliorating and/or preventing leptin resistance, and use thereof
CN102574890B (zh) * 2010-08-23 2015-03-11 苏州润新生物科技有限公司 某些化学个体、组合物及方法
EP2804865B1 (en) * 2012-01-20 2015-12-23 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as p2x7 receptor antagonists
NZ702169A (en) * 2012-05-25 2016-10-28 Berg Llc The use of heat shock protein 90 (hsp90) modulators for the treatment of metabolic syndrome
AU2013323528B2 (en) * 2012-09-27 2016-11-10 The Children's Medical Center Corporation Compounds for the treatment of obesity and methods of use thereof
CN103524592B (zh) * 2013-09-27 2015-08-05 安徽医科大学 一种雷公藤红素衍生物、该衍生物的生物盐及其制备方法与用途

Also Published As

Publication number Publication date
RU2016141567A (ru) 2018-04-27
RU2016141567A3 (pt) 2018-04-27
AU2015235979B2 (en) 2019-05-02
US20190062254A1 (en) 2019-02-28
WO2015148802A1 (en) 2015-10-01
US20150274634A1 (en) 2015-10-01
CA2944030A1 (en) 2015-10-01
RU2706239C2 (ru) 2019-11-15
AU2019202601A1 (en) 2019-05-02
CN117357538A (zh) 2024-01-09
BR112016021985A2 (pt) 2017-08-15
JP2017513824A (ja) 2017-06-01
CA3044998A1 (en) 2015-10-01
US20180194709A1 (en) 2018-07-12
CA2944030C (en) 2019-06-04
EP3122347A1 (en) 2017-02-01
EP3122347B1 (en) 2020-06-03
ES2813424T3 (es) 2021-03-23
CN107073016A (zh) 2017-08-18
AU2015235979A1 (en) 2016-10-20
BR112016021985B1 (pt) 2022-08-30

Similar Documents

Publication Publication Date Title
BR112016021985A8 (pt) formulação farmacêutica e composto
MX2022009595A (es) Sales de berberina, sales ursodesoxicolicas y combinaciones, metodos de preparacion y aplicacion de las mismas.
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
BR112017006957A2 (pt) formulações farmacêuticas para a liberação por via oral de fármacos do tipo de peptídeo ou proteína
BR112015000136A2 (pt) fibra alimentar para uso no tratamento de um efeito colateral gastrintestinal de uma nutrição ou medicamento
PH12014502058A1 (en) Pharmaceutical composition comprising empagliflozin and antiobesity drug
AU2018256619A1 (en) Compounds for the treatment of obesity and methods of use thereof
BR112016027041A8 (pt) combinações farmacêuticas para tratamento do câncer
CL2019003091A1 (es) Terapia de combinación.
BR112014018953A8 (pt) Derivados de lupano triterpenoide e uso farmacêutico dos mesmos
BR112017009510A2 (pt) composições compreendendo ciclosporina
BR102018016746A8 (pt) Composição farmacêutica para prevenção de obesidade induzida por dieta
MX2022013450A (es) Formulaciones farmaceuticas.
CL2017000884A1 (es) Composición farmacéutica para usarse en el tratamiento o la prevención de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugía de derivación gástrica
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
BR112015031835A8 (pt) agentes terapêuticos, combinação dos referidos agentes e agente terapêutico adicional, uso dos referidos agentes e da referida combinação para fabricação de medicamento para a profilaxia e/ou tratamento de distúrbios do movimento hipercinético
ECSP19024033A (es) Composiciones de tesofensina
BR112019008370A2 (pt) composição para tratamento preventivo ou curativo de distúrbios hepáticos
BR112018016817A2 (pt) composição farmacêutica e método de tratamento da deficiência do hormônio do crescimento
BR112017000529A2 (pt) comprimido dispersível de misoprostol
BR112015028581A2 (pt) composição farmacêutica de dosagem baixa, utilização do ácido, método para o tratamento da doença inflamatória e composição farmacêutica
BR112016018009A8 (pt) composição de cinamaldeído e zinco e seu uso
BR112018002433A2 (pt) composição farmacêutica para tratamento da enxaqueca

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: THE GENERAL HOSPITAL CORPORATION (US)

B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/03/2015, OBSERVADAS AS CONDICOES LEGAIS